Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid 3Leukemia 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Recurrence 1P1b: Advanced Solid Tumors 1Malignant Solid Tumors 1Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Burkitt Lymphoma 1Brain Neoplasms 1Blast Crisis 1Advanced Solid Tumors 1

Interventions

asciminib 1Paclitaxel 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × P1b: Advanced Solid Tumors × asciminib × Clear all
NCT04492033 2025-01-27

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Handok Inc.

Phase 1/2 Terminated
41 enrolled
GastrointestinalOther solid neoplasm

P1b: Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡